Emulate, Inc., a Boston, MA-based provider of next generation in vitro models, closed an $82m Series E financing round.
The round, which brought total funding raised to date to nearly $225m, was led by existing investor Northpond Ventures with participation from Perceptive Advisors.
The company intends to use the funds to continue to facilitate the creation of new human-relevant organ-on-a-chip models in immunology, neuroinflammation, tumor modeling, and more and extend operations in the Asia Pacific region with two new distributors.
Led by Jim Corbett, CEO, Emulate develops and manufactures next-generation in vitro models that enable researchers to replicate and study human biology and disease, helping them understand and predict drug response with greater precision and detail than possible with conventional cell culture or animal-based methods. Organ-on-a-chip technology by Emulate provides flexible microenvironments containing tiny hollow channels lined with living cells and tissues that can be subjected to mechanical forces that mirror breathing or digestion in the human body. The technology is used by leading academic researchers, government entities, and many of the largest pharmaceutical companies to better understand the biology of human disease.
FinSMEs
07/09/2021